Equities

Inhibrx Biosciences Inc

INBX:NSQ

Inhibrx Biosciences Inc

Actions
  • Price (USD)16.52
  • Today's Change-0.06 / -0.36%
  • Shares traded9.64k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024 15:27 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. The Company’s clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106. INBRX-109 is a tetravalent agonist of death receptor 5 (DR5) that is designed with its proprietary single domain antibody, or sdAb, platform to drive cancer-selective programmed cell death and to maximize potency while minimizing on-target liver toxicity arising from hepatocyte apoptosis. INBRX-106 is a hexavalent OX40 agonist, being investigated as a single agent and in combination with Keytruda, a PD-1 blocking checkpoint inhibitor, in patients with locally advanced or metastatic solid tumors. INBRX-106 is a precisely engineered hexavalent sdAb-based therapeutic candidate targeting OX40, designed to be an optimized agonist of this co-stimulatory receptor.

  • Revenue in USD (TTM)1.85m
  • Net income in USD1.63bn
  • Incorporated2024
  • Employees166.00
  • Location
    Inhibrx Biosciences Inc11025 N. Torrey Pines Road, Suite 140LA JOLLA 92037United StatesUSA
  • Phone+1 (858) 795-4220
  • Fax+1 (302) 636-5454
  • Websitehttps://inhibrx.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Telomir Pharmaceuticals Inc0.00-18.74m124.07m1.00--79.14-----0.6855-0.68550.000.05290.00----0.00-467.16---686.91-------------0.92990.00-------1,430.39------
Hongchang International Co Ltd4.65m-292.22k125.56m8.00--3.20--27.01-0.0006-0.00060.00930.07570.16475.028.74---0.8827-7.98-0.9331-10.943.9211.47-5.36-64.883.77--0.2642--3,289.22---42.63------
Elutia Inc24.99m-70.10m129.43m54.00------5.18-3.05-2.861.12-2.280.53032.325.08462,722.20-148.77-42.93-1,212.93-79.3442.4643.32-280.53-64.160.6842-0.6561-----49.69-8.71-25.39--12.74--
Global Pharmatech Inc.3.18m-2.24m138.32m217.00--1.02--43.51-0.0964-0.09640.13670.34280.22921.593.5714,649.77-16.44---22.55--46.21---71.75--1.62-9.870.2223--32.43---142.03------
Scilex Holding Co50.83m-171.53m147.53m113.00------2.90-1.40-1.400.4425-1.770.44015.221.55484,123.80-102.93------68.24---233.88--0.1853-3.72----22.90---614.67------
LifeVantage Corp196.01m4.13m172.10m217.0043.056.1922.660.8780.31920.319215.272.223.062.5071.64903,290.306.469.9510.1715.5579.2181.452.113.080.9923559.360.0026.95-6.20-2.4015.63-16.94-2.18--
Mediwound Ltd20.14m-19.97m182.40m100.00--8.79--9.06-2.16-2.162.181.920.33115.536.55201,410.00-32.83-24.48-49.28-32.9213.2543.27-99.17-38.431.51-3.260.2623---29.4840.6065.73--64.66--
Scpharmaceuticals Inc24.05m-60.64m196.61m135.00--15.35--8.18-1.56-1.560.61870.2560.26780.65636.23178,133.30-67.52-38.23-75.77-42.3171.15---252.18-1,360.163.66-13.660.8121-------48.79------
Eton Pharmaceuticals Inc31.38m-6.69m236.92m30.00--17.54--7.55-0.2596-0.25961.220.52291.008.827.891,046,033.00-21.31-46.22-38.27-58.2059.4872.16-21.31-76.861.28--0.2571--48.90--89.62--26.85--
Inhibrx Biosciences Inc1.85m1.63bn240.01m166.000.13681.090.1466129.53121.21121.210.043415.150.0079--4.8611,162.65693.63-77.06815.31-93.91----88,264.55-1,590.91---21.960.00---17.88-26.85-66.20--26.30--
Lifecore Biomedical Inc128.45m5.71m258.53m524.00190.04--17.962.010.03690.05953.821.280.52172.014.96245,124.002.32-5.912.74-8.3334.6531.014.45-19.160.8030.1250.7641--24.20-25.46114.5334.47-16.72--
Precigen Inc4.39m-135.38m271.15m202.00--5.56--61.78-0.5407-0.54070.01760.17090.0313--4.7121,727.72-96.46-31.50-119.34-38.63-13.5644.00-3,084.55-232.32----0.00---76.87-47.16-20.22---48.30--
Sanara Medtech Inc72.41m-6.57m302.65m107.00--7.26--4.18-0.7788-0.77888.624.771.101.868.13676,731.00-10.16-17.73-12.08-22.0789.7388.08-9.23-17.131.49-4.880.2577--41.7761.9345.79--99.09--
Data as of Nov 13 2024. Currency figures normalised to Inhibrx Biosciences Inc's reporting currency: US Dollar USD

Institutional shareholders

39.85%Per cent of shares held by top holders
HolderShares% Held
Viking Global Investors LPas of 30 Jun 20241.79m12.35%
Perceptive Advisors LLCas of 30 Jun 20241.06m7.35%
BlackRock Fund Advisorsas of 30 Jun 2024624.04k4.31%
Walleye Capital LLCas of 30 Jun 2024475.00k3.28%
The Vanguard Group, Inc.as of 30 Jun 2024463.91k3.21%
Slotnik Capital LLCas of 30 Jun 2024341.61k2.36%
Millennium Management LLCas of 30 Jun 2024303.20k2.09%
TIG Advisors LLCas of 30 Jun 2024243.65k1.68%
Morgan Stanley & Co. LLCas of 30 Jun 2024235.56k1.63%
Ikarian Capital LLCas of 30 Jun 2024230.00k1.59%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.